An Investigational Vaccine in Reducing the Incidence of Anogenital Warts in Young Men

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 30 Nov 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
Indications Anal cancer; Anal intraepithelial neoplasia; Genital warts; Human papillomavirus infections; Penile cancer
Focus Adverse reactions; Registrational; Therapeutic Use
Sponsors Merck & Co; Merck Sharp & Dohme

28 Nov 2023 Results published in the Journal of Infectious Diseases
05 Jun 2018 Results reporting the end-of-study analysis of a long-term follow up (LTFU) extension study that assessed the effectiveness and immunogenicity of the qHPV vaccine through 10 years after the first dose presented at the 54th Annual Meeting of the American Society of Clinical Oncology
11 Apr 2017 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com